BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 34489209)

  • 41. [Treatment strategy for immunoglobulin light chain amyloidosis].
    Fuchida SI
    Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.
    Palladini G; Sachchithanantham S; Milani P; Gillmore J; Foli A; Lachmann H; Basset M; Hawkins P; Merlini G; Wechalekar AD
    Blood; 2015 Jul; 126(5):612-5. PubMed ID: 25987656
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure.
    Sperry BW; Ikram A; Hachamovitch R; Valent J; Vranian MN; Phelan D; Hanna M
    J Am Coll Cardiol; 2016 Jun; 67(25):2941-8. PubMed ID: 27339491
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
    Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
    Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
    Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
    Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].
    Shen KN; Miao HL; Gao YJ; Cao XX; Zhou DB; Su W; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):31-34. PubMed ID: 35231990
    [No Abstract]   [Full Text] [Related]  

  • 47. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
    Kastritis E; Leleu X; Arnulf B; Zamagni E; Cibeira MT; Kwok F; Mollee P; Hájek R; Moreau P; Jaccard A; Schönland SO; Filshie R; Nicolas-Virelizier E; Augustson B; Mateos MV; Wechalekar A; Hachulla E; Milani P; Dimopoulos MA; Fermand JP; Foli A; Gavriatopoulou M; Klersy C; Palumbo A; Sonneveld P; Johnsen HE; Merlini G; Palladini G
    J Clin Oncol; 2020 Oct; 38(28):3252-3260. PubMed ID: 32730181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.
    Milani P; Sharpley F; Schönland SO; Basset M; Mahmood S; Nuvolone M; Kimmich C; Foli A; Sachchithanantham S; Merlini G; Wechalekar A; Palladini G; Hegenbart U
    Amyloid; 2020 Dec; 27(4):231-236. PubMed ID: 32449385
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
    N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.
    Chitimus DM; Berling E; Garderet L; Venturelli N; Malfatti E; Authier FJ; Nicolas G; Laforêt P; Lefeuvre C
    Eur J Neurol; 2023 Mar; 30(3):745-748. PubMed ID: 36403110
    [TBL] [Abstract][Full Text] [Related]  

  • 51. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
    Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
    J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
    Gustine JN; Staron A; Mendelson L; Joshi T; Gopal DM; Siddiqi OK; Ruberg FL; Sanchorawala V
    Blood Adv; 2023 Oct; 7(20):6080-6091. PubMed ID: 37581513
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.
    Palladini G; Milani P; Foli A; Obici L; Lavatelli F; Nuvolone M; Caccialanza R; Perlini S; Merlini G
    Haematologica; 2014 Apr; 99(4):743-50. PubMed ID: 24213149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis.
    Liu B; Bai M; Wang Y; Wang D; Zhao J; Li L; Dong R; Sun S
    Eur J Intern Med; 2019 Nov; 69():32-41. PubMed ID: 31447275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
    Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z
    BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis.
    Heybeli C; Bentall A; Wen J; Alexander MP; Buadi FK; Cosio FG; Dean PG; Dispenzieri A; Dingli D; El Ters M; Gertz MA; Hatem A; Kapoor P; Khamash H; Kourelis T; Kumar S; Lorenz EC; Mai M; Muchtar E; Murray DL; Prieto M; Schinstock CA; Stegall MD; Warsame R; Leung N
    Kidney Int; 2021 Mar; 99(3):707-715. PubMed ID: 32712168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Analysis of clinical characteristics and outcome of patients with very high risk primary immunoglobulin light-chain amyloidosis].
    Feng J; Huang XF; Zhang CL; Shen KN; Zhang CL; Sun J; Tian Z; Cao XX; Zhang L; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):107-111. PubMed ID: 28279033
    [No Abstract]   [Full Text] [Related]  

  • 58. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients -  single center experience].
    Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
    Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.
    Lee JY; Lim SH; Kim SJ; Lee GY; Lee JE; Choi JO; Kim JS; Kim HJ; Lee SY; Min JH; Jeon ES; Kim K
    Amyloid; 2014 Dec; 21(4):261-6. PubMed ID: 25248716
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of systemic AL amyloidosis: about 25 cases].
    Eddou H; Zinebi A; Maaroufi HE; Moudden MK; Doghmi K; Mikdame M; Baaj ME
    Pan Afr Med J; 2017; 28():160. PubMed ID: 29541306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.